CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients.
Cyclin B2 (CCNB2), a member of cyclin family proteins, serves a key role in progression of G2/M transition. The clinical value of CCNB2 in non-small cell lung cancer is still unknown. The aim of our study is to identify the role of CCNB2 in NSCLC patients. The status of CCNB2 in NSCLC tissues and normal lung tissues was observed in Gene Expression Omnibus (GEO: GSE19804). CCNB2 mRNA and protein expressions were detected in NSCLC and normal lung tissues by using Real-time PCR and immunohistochemistry. The association of CCNB protein expression with clinical characteristics of 186 NSCLC patients was analyzed by immunohistochemistry. Based on microarray data (GEO: GSE19804), we observed that CCNB2 was significantly overexpressed in NSCLC tissues compared with paired adjacent normal lung tissue. Furthermore, we verified mRNA and protein levels of CCNB2 expression were both increased in NSCLC tissues. We found high levels of CCNB2 protein were positively associated with the status of differentiated degree, tumor size, lymph node metastasis, distant metastasis, and clinical stage. Meanwhile, CCNB2 protein overexpression was an independent unfavorable prognostic factor for the overall survival of patients with NSCLC. In conclusion, overexpression of CCNB2 protein is associated with clinical progression and poor prognosis in NSCLC.
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xiaotao
X
Qian
School of Information Technology, Henan University of Traditional Chinese Medicine, Zhengzhou450008, China.
Xuekun
X
Song
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yuan
Y
He
Department of Radiontherapy, Huanggang Central Hospital, Huanggang 438000, China.
Zhiyong
Z
Yang
Department of Thoracic Surgery, Fuyang Second People's Hospital, Fuyang 236015, China.
Tao
T
Sun
Department of Oncology, Fuyang Tumor Hospital, Fuyang 236018, China.
Jing
J
Wang
Department of Infection and Liver Diseases, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Guiqi
G
Zhu
Department of Pathology, Fifth People's Hospital of Fuyang, Fuyang 23600, China.
Weihai
W
Xing
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: ycx_6026@163.com.
Changxuan
C
You
D000328:Adult; D000368:Aged; D044466:Asian People / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology*; D056765:Cyclin B2 / Q000235:genetics*; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D015996:Survival Rate; D055815:Young Adult
D014408:Biomarkers, Tumor; C503758:CCNB2 protein, human; D056765:Cyclin B2; D012333:RNA, Messenger
Biomarker; CCNB2; NSCLC; Prognosis